This segment focuses on the research, development, and clinical trials of bispecific antibody therapeutics for various cancers. Merus utilizes its proprietary Multiclonics® platform to create full-length human bispecific antibodies. The primary R&D activities include preclinical studies, Phase 1/2 and Phase 3 clinical trials, and manufacturing process development. The therapeutic areas covered include metastatic breast cancer, solid tumors, advanced non-small cell lung cancer, and relapsed/refractory T cell lymphoma. The goal is to improve patient outcomes by providing targeted therapies with the potential for enhanced efficacy and reduced side effects. Market positioning is based on the innovative Multiclonics® platform and strategic collaborations. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a key aspect of this segment, with a focus on safety and efficacy. Partnerships with companies like Betta Pharmaceuticals and Incyte Corporation are crucial for advancing the pipeline.